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Summary
Wnt5a is a member of the Wnt family of secreted glycoproteins that play essential organizing roles in development. Similar
to other Wnt members, Wnt5a can upregulate cell proliferation and has been proposed to have oncogenic function. Here
we report that Wnt5a signals through the noncanonical Wnt/Ca pathway to suppress cyclin D1 expression and negatively
regulate B cell proliferation in a cell-autonomous manner. Wnt5a hemizygous mice develop myeloid leukemias and B cell
lymphomas that are clonal in origin and display loss of Wnt5a function in tumor tissues. Furthermore, analysis of human
primary leukemias reveals deletion of the WNT5A gene and/or loss of WNT5A expression in a majority of the patient
samples. These results demonstrate that Wnt5a suppresses hematopoietic malignancies.
Introduction In some contexts, Wnt5a can act similar to other Wnt family
members and bind with Frizzled (Fz) receptors located on the
Wnt proteins are a large family of cysteine-rich, secreted glyco- cell surface and activates cytosolic Dishevelled (Dsh) proteins,
protein signaling molecules. At least 19 Wnt members have leading to stabilization of -catenin (He et al., 1997). Accumula-
been identified in mammals to date. The members exhibit unique tion of -catenin results in its nuclear translocation and activa-
expression patterns and distinct functions in development, al- tion of Lef /Tcf transcription factors (Behrens et al., 1996; Mole-
though some overlap is observed (Bouillet et al., 1996; Stark et naar et al., 1996; Toyofuku et al., 2000). In addition to utilizing
al., 1994; Takada et al., 1994; van Gijn et al., 2002; Wolda et al., the canonical Wnt signaling pathway, studies of convergent
1993; Yamaguchi et al., 1999). Wnt1, the initial member of the extension movements of Xenopus embryos and in zebrafish
family, was discovered as a protooncogene that induced mam- suggested that Wnt5a also signals through a noncanonical Ca
mary tumor development when overexpressed in mice (Nusse
pathway (Kuhl et al., 2000; Wallingford et al. 2001; Yamanakaand Varmus, 1982). In addition to Wnt1, other Wnt family mem-
et al., 2002; Myers et al. 2002). Binding of Wnt5a to Fz will, inbers have been found to have transforming abilities and have
some context, signal through heterotrimeric G proteins to acti-been classified based upon their ability to induce transformation
vate PLC, inducing phospholipid turnover in endoplasmic reticu-of the mouse mammary epithelial cell line, C57MG. Wnt1, 3A,
lum membranes and triggering the release of intracellular Caand 7A are members of the highly transforming class, whereas
(Slusarski et al., 1997a, 1997b), which activates protein kinase CWnt2, 5b, and 7b also induce cell transformation but with a
(PKC) (Sheldahl et al., 1999) and calmodulin-dependent proteinlower frequency. In contrast, Wnt4, 5a, and 6 fail to induce cell
transformation in these assays (Wong et al., 1994). kinase II (CamKII) (Kuhl et al., 2000), leading to the block of
S I G N I F I C A N C E
Wnt5a is a member of the Wnt family of secreted signaling molecules important in development and in cancer. Wnt5a has been
previously shown to have growth-enhancing or oncogenic potential: Wnt5a upregulates proliferation of progenitor cells common
to many structures in mice, Wnta5a expression is upregulated in a variety of human primary tumor samples, and WNT5A facilitates
cell invasion in human metastatic melanoma. Here we demonstrate that Wnt5a negatively regulates B cell proliferation in a cell-
autonomous manner. Deletion of the Wnt5a gene, loss of Wnt5a expression, and increased cyclin D1 expression is observed in
mouse and human B cell lymphomas and myeloid leukemias. These results demonstrate that a member of the Wnt family of
protooncogenes can function as a tumor suppressor.
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Figure 1. Wnt5a expression in hematopoietic tissues and cells
Total RNA was extracted from indicated samples and analyzed for Wnt5a expression by RT-PCR. The amplified products were detected by Southern analysis
using a Wnt5a-specific oligo probe. RT-PCR analysis of mouse Gapdh or Hprt expression was performed as a positive control.
A: Wnt5a expression in B220 cells and in cultured primary stromal cells.
B: Expression of Wnt5a in mouse hemotopoietic progenitor and mature cells.
C: Wnt5a expression in adult hemotopoietic tissues and T cell lymphoma cell lines: WEHI 7.1 and EL4; myeloid progenitor cell line: FDC-P1; and myeloid-
macrophage cell lines: J774 and RAW309.
-catenin signaling cascade (Torres et al., 1996; Kuhl et al., we report that Wnt5a is widely expressed in murine hematopoi-
etic tissues and that Wnt5a signals in a cell-autonomous manner2001; Ishitani et al., 2003) and to the activation of calcium-
sensitive transcription factor NFAT (Saneyoshi et al., 2002). via the noncanonical Wnt/Ca pathway to inhibit B cell prolifer-
ation by negatively regulating the response of B cells to IL-7Functional analysis of many of the Wnt genes has been
performed via gene targeting experiments in mouse embryonic and suppressing cyclin D1 expression. Furthermore, a subset
of Wnt5a heterozygous mice develop either spontaneous B cellstem cells. Many of the resulting mice display development
defects in tissue patterning or morphogenesis, indicating that lymphoma that is clonal in origin or chronic myeloid leukemia,
and tumors arising in the Wnt5a heterozygous mice display lossthe Wnt family members play critical roles in mammalian devel-
opment (Wodarz and Nusse, 1998; Yamaguchi, 2001). We have of Wnt5a function. Finally, analysis of primary tumors isolated
from patients with acute lymphocytic leukemia and acute my-previously generated Wnt5a-deficient mice through gene tar-
geting in mouse ES cells and found that Wnt5a was essential eloid leukemia reveals loss of WNT5A and WNT5A gene expres-
sion in a majority of these human samples. These results indicatefor proper development (Yamaguchi et al., 1999). Wnt5a null
mice exhibit perinatal lethality and fail to extend multiple struc- that Wnt5a functions in a cell-autonomous manner to negatively
regulate B cell proliferation and suppresses hematopoietic ma-tures that outgrow from the primary body axis. Interestingly,
this defect in morphogenesis was not due to loss of tissue lignancies.
identity, but rather to a reduced rate of cell proliferation in tissue
underlying the outgrowing structures. These findings suggest Results
that Wnt5a is capable of inducing cell proliferation. Several other
lines of evidence further suggest that Wnt5a has growth-enhancing Wnt5a expression in hematopoietic tissues
or oncogenic properties. Addition of exogenous Wnt5a to the To determine the pattern of Wnt5a expression in mouse hemato-
media of cultured cells stimulated hematopoietic stem cell prolif- poietic tissues, RT-PCR was performed. Wnt5a is expressed in
eration, including lymphoid and myeloid progenitor cells, and splenic B cells, fetal liver B cell progenitors, and in primary
intraperitoneal injection of Wnt5a into mice has been found cultures of fetal liver and bone marrow stromal cells (Figure
recently to augment the repopulating capacity of transplanted 1A). During fetal hematopoiesis, Wnt5a is transcribed in cell
human primitive hematopoietic stem cells (Murdoch et al., 2003). populations enriched for fetal liver hematopoietic stem
Furthermore, upregulation of WNT5A has been observed in hu- cells (HSC) (Sca-1/c-kit/AA4.1/Lin cells) and progenitor
man primary breast cancer, gastric cancer, lung cancer, prostate cells (AA4.1 cells) (Figure 1B). Wnt5a is also expressed in adult
cancer, and melanoma (Austin et al., 1997; Iozzo et al., 1995; bone marrow (BM) HSC (Rho-123low/Sca-1/c-kit/Lin) that is
highly enriched for HSC activity (Jordan et al., 1995; PetrenkoLejeune et al., 1995; Saitoh and Katoh, 2001; Van Den Berg et
al., 1998), and WNT5A has been reported to facilitate cell invasion et al., 1999; Phillips et al., 2000). Interestingly, Wnt5a transcripts
are not observed in more heterogeneous populations of HSCin human metastatic melanoma (Weeraratna et al., 2002).
Wnt5a heterozygous mice are normal, viable, and fertile (Lin/Sca-1BM cells) or progenitors (Lin/Sca-1 cells). Wnt5a
expression is upregulated in committed progenitors and mature(Yamaguchi et al., 1999). Surprisingly, some of the Wn5a/
mice developed B cell lymphomas. This prompted us to examine blood cell types (Lin bone marrow cells). Analysis of a panel
of mouse lineage-specific hematopoietic cell lines demonstratesthe role of Wnt5a in B cell proliferation and differentiation. Here
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Figure 2. Expansion and hyperproliferation of B lymphocytes in Wnt5a null mice
A, B, and C: Flow cytometry analysis of antibody-stained E19 Wnt5a/ and / FL cells.
D: Methylcellulose colony-forming assay for B cells using wild-type and Wnt5a null FL cells. The results are given as the number of colonies formed per 105
cells.
E: BrdU incorporation assays. B220-positive and -negative FL cells, labeled in vivo with BrdU, were stained with anti-BrdU-FITC and analyzed by flow cytometry.
Error bars represent means  SD (D and E).
that Wnt5a is ubiquitously expressed in different stages of B immature B cells (IgM) are very rare in E19 fetal liver, we assayed
for this population in Wnt5a null and wild-type FL by in vitro culturecell, T cell, and myeloid cell development (Figure 1C). These
results demonstrate that Wnt5a is expressed widely in hemato- of FL in the presence of IL-7. After 8 days in culture, Wnt5a null
FL produced 1.7 times as many immature B cells as did wild-poietic tissues.
type FL (Figure 2C). Thus, absence of Wnt5a does not block B
cell development from pro-B to immature B stage.Absence of Wnt5a increases B cell proliferation
in a cell-autonomous manner To confirm the increase in progenitor B cells in Wnt5a null FL,
colony-forming assays were performed using FL cells harvestedDue to the perinatal lethality of Wnt5a null mice, examination
of the Wnt5a effects on B cells was restricted to fetal liver (FL), from wild-type or Wnt5a null embryos at E19. Nearly twice as
many colonies were detected withWnt5a null FL than with wild-which supports B cell development from embryonic day 13 (E13)
to birth. E19 FL cells were isolated and stained with anti-B220 type FL when grown in methylcellulose cultures supplemented
with IL-7, which facilitates growth of pro-B and pre-B cell colo-antibody, a B cell surface marker, and analyzed by flow cytome-
try. Wnt5a null mice display a 35% increase in the proportion nies (StemCell Technologies) (Figure 2D). In addition to forming
more colonies, FL cells from Wnt5a null mice also formed largerof B lineage cells (Figure 2A) and a 55% increase in the absolute
numbers of B cells. To examine if absence of Wnt5a alters sized colonies (data not shown), suggesting that Wnt5a null B
cells proliferate faster than wild-type B cells in these assays.B cell differentiation, staining with combinations of antibodies
against B220, CD43, and IgM was performed. Increased num- To determine whether the augmented B cell numbers in
Wnt5a null FL are due to higher rates of cell proliferation or duebers of pro-B cells (B220/CD43) and pre-B cells (B220/
CD43) were present in Wnt5a null FL (Figure 2B). Because to increased resistance of Wnt5a null cells to apoptosis, BrdU
CANCER CELL : NOVEMBER 2003 351
A R T I C L E
Figure 3. Wnt5a regulates B cell proliferation in a cell-autonomous manner
Tissues from mice transplanted with wt or Wn5a/ FL were harvested, stained with antibodies as indicated, and analyzed by flow cytometry.
A: Representative result of flow cytometric analysis.
B: Absolute numbers of different B cell populations.
incorporation assays and TUNEL (terminal deoxynuclotidyl in mice transplanted with Wnt5a null FL cells than those rescued
with wild-type FL (Figure 3). Increased numbers of mature follic-transferase-mediated dUTP nick end-labeling) assays were per-
formed on FL cells. Wnt5a null mice contain 50% more BrdU- ular B cells (IgMlow/IgDhigh) were also observed in the peripheral
blood of recipients transplanted with Wnt5a null FL (data notand B220-positive cells than wild-type mice (Figure 2E), indicat-
ing that Wnt5a negatively regulates B cell proliferation. The shown). These findings indicate that the increased rate of B cell
proliferation observed in Wnt5a-deficient mice is due to loss of adifference in cell proliferation rates between Wnt5a null and
wild-type mice is less profound in the B220-negative population. cell-intrinsic signal that cannot be complemented by physiologic
levels of Wnt5a present in serum or in the stroma.No difference was found in the number of TUNEL-positive cells
in E19 wild-type and Wnt5a mutant B220 cells (data not
shown). Taken together, we concluded that increase of the B Wnt5a inhibits the response of B cells to IL-7
B cell progenitors are critically dependent on the cytokine in-lineage cell compartment in Wnt5a null FL results from increased
proliferation of B cells and not from alteration in the resistance terleukin-7 (IL-7) for growth (Fry and Mackall, 2002), and the
increase in Wnt5a null B cell numbers and size of the coloniesof B cells to apoptosis.
To determine whether Wnt5a inhibits B cell proliferation in observed in the colony-forming assays suggests that hyperproli-
feration in the absence of Wnt5a could result from alterationsa cell-autonomous manner, we performed adoptive transfer ex-
periments. Wild-type or Wnt5a null FL cells were transplanted in the responsiveness of the B cells to IL-7. To test this possibil-
ity, [3H] thymidine uptake assays were performed on FACS-into lethally irradiated Rag1/ mice. Six weeks post-transplant,
bone marrow, spleen, and peripheral blood cells were harvested sorted FL B cells cultured in the presences or absence of IL-7
(Figure 4A). Wild-type and mutant B cells have similar [3H] thymi-and examined by flow cytometry. Both the percentage and
the absolute numbers of pro-B (B220/CD43), pre-B (B220/ dine uptake in the absence of IL-7. However, Wnt5a null B
cells display an increased rate of [3H] thymidine uptake in theCD43/IgM), IgM B cells (B220/IgM) in bone marrow and
mature follicular B cells (IgMlow/IgDhigh) in the spleen were greater presence of IL-7 relative to wild-type samples, suggesting that
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Figure 4. Absence of Wnt5a increases B200 cell responsiveness to IL-7 in a cell-transic manner
A: [3H] thymidine uptake assay was performed on cultured B220-positive cells, sorted from wild-type and Wnt5a null FL, in the presence or the absence
of IL-7.
B: The sorted Wnt5a null FL B220 cells were cultured on stromal layers derived from wild-type or Wnt5a null FL in the presence or the absence of IL-7, and
[3H] thymidine uptake assay was performed as in Figure 4A. Thymidine uptake of FL B220 cells was adjusted by subtracting H3 uptake of stromal cells.
Error bars represent means  SD (A and B).
Wnt5a alters the responsiveness of B cells to IL-7. We also decreased in the absence of Wnt5a (Figure 5E), further sug-
gesting that absence of Wnt5a leads to a reduction in PKCassessed the proliferation rate of Wnt5a null B220 cells when
cultured on stromal cell feeder layers derived from either wild- activity. These results indicate that Wnt5a is signaling via the
Wnt/Ca pathway to activate CamKII and PKC. Cyclin D1 andtype FL or Wnt5a null FL. There was no difference in the re-
sponse of Wnt5a null B220 cells to IL-7 stimulation when plated c-myc are cell cycle regulatory genes whose expression was
previously reported to be upregulated in response to Wnt1-on stromal layers that contained or lacked Wnt5a (Figure 4B).
The inability of the wild-type stromal cells to compensate dys- mediated activation of the -catenin pathway. We examined
the effect of Wnt5a upon regulation of these two genes usingfunction of Wnt5a in the B cells indicates that Wnt5a-mediated
suppression of IL-7 stimulation is cell autonomous and is consis- real-time PCR (Figure 6A). The threshold cycle numbers (CT) for
cyclin D1 in wild-type FL was 28.5 versus 26.8 for Wnt5 null FL.tent with the results of the FL adoptive transfer experiment.
Control experiments utilizing cyclin D1 cDNA as input template
confirmed that a two cycle difference in threshold valuesWnt5a signals through the noncanonical Wnt/Ca
pathway and downregulates cyclin D1 expression equates to a 4-fold difference in template concentration, indicat-
ing that cyclin D1 expression in Wnt5 null FL was increasedWnt5a has been proposed to activate both the canonical Wnt/
-catenin pathway (He et al., 1997; Toyofuku et al., 2000) and 4-fold relative to wild-type levels. The CT for c-myc in Wnt5a
wild-type and null cells was 26.3 and 26.5, respectively, sug-Wnt/Ca pathway (Figure 5A), and activation of the Wnt/Ca
pathway has been suggested to block the Wnt/-catenin signal- gesting no significant difference in c-myc expression levels in
the presence or absence of Wnt5a.ing cascade (Torres et al., 1996; Kuhl et al., 2001; Ishitani et
al., 2003). To dissect the mechanistic pathway utilized by Wnt5a To further confirm the ability of Wnt5a to downregulate cyclin
D1 and inhibit cell proliferation, we transduced Wnt5a into twoin regulating B cell proliferation, we analyzed -catenin levels
in wild-type and Wnt5a null FL. No difference was detected in independent mouse B cell lines. 7C6 cells and 1–8 cells are
Abelson leukemia virus-transformed B cells lines that lack-catenin levels in whole-cell or in nuclear extracts between the
two genotypes, suggesting that Wnt5a was neither activating Wnt5a expression. Mouse Wnt5a cDNA was cloned into an
MSCV2.2IRES-GFP vector, and MSC-Wnt5a-GFP or MSC-GFPnor inhibiting the canonical Wnt/-catenin pathway in FL (Figure
5B). Therefore, we examined the Wnt/Ca pathway. CamKII (empty vector) DNA was electroporated into 7C6 cells and 1–8
cells. Transduced cells were recovered by FACS and analyzedactivity assays showed that Wnt5a null FL cells possess 40%
less activity than wild-type FL cells (Figure 5C), even though for proliferation and for expression of Wnt5a and cyclin D1.
Transduction of Wnt5a into 7C6 or 1–8 cells increased the levelWestern blot analysis revealed equal amounts of total CamKII in
both samples (data not shown). Immunoblotting with antibodies of phosphorylated PKC and decreased cyclin D1 levels, indicat-
ing that Wnt5a expression activates the noncanonical signalingagainst phosphorylated PKC demonstrated a reduction in acti-
vated PKC in both Wnt5a null FL and in Wnt5a null B220 cells pathway and inhibits cyclin D1 (Figure 6B). BrdU staining of the
transduced cells revealed that expression of Wnt5a reducedsorted from E18 FL (Figure 5D). In addition, PKC has been found
to activate the c-jun amino-teminal kinase (JNK) (Mitsutake et proliferation in both B cell lines (Figure 6C). These data are
consistent with our in vivo results indicating that Wnt5a nega-al., 2001; Saneyoshi et al., 2002). Although total JNK levels were
equal in Wnt5a wild-type and null fetal liver, activated JNK was tively regulates B cell proliferation in a cell-autonomous manner
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Figure 5. Wnt5a signals through Ca pathway and not the -catenin pathway in FL
A: Schematic presentation of Wnt5a signaling pathways.
B: Whole-cell and nuclear -catenin levels in wild-type and Wnt5a null FL. Antibodies against mouse -tubulin and Ini1 are used as protein loading controls
for whole-cell and nuclear extracts, respectively.
C: CamKII activity assays. Wild-type FL CamKII activity is presented as 100% and mutant FL is given as CamKII percentage relative to wild-type. Error bars
represent mean  SD.
D: Western blot on E19 FL to detect phosphorylated PKC. Antibodies against phosphorylated PKC (Pan) or -actin (for verification of equal loading) were
used.
E: JKN kinase activity was performed using immunoprecipitates of JNK. The immunocomplexes were assayed for JNK activity using an antibody against
phosphorylated c-jun. Total JNK was detected by Western blot analysis using antibodies against JNK.
by activating the Wnt/Ca pathway and inhibiting cyclin D1 mas as determined by B220 staining, with the remainder stain-
expression. ing negative for B220, positive for chloroacetate esterase, and
classified as myeloid leukemias. Five representative B cell lym-
Wnt5a heterozygous mice develop B cell lymphoma phomas were further analyzed to determine if the lymphomas
and chronic myeloid leukemia with loss were clonal in origin. PCR assays performed using DNA isolated
of heterozygosity for Wnt5a function from tumor tissues revealed specific rearrangements of the VDJ
To explore the role of Wnt5a in tumorigenesis, we performed region of the immunoglobulin heavy chain locus in each tumor,
tumor assays on cohorts of Wnt5a heterozygous mice and on indicating that the B cell lymphomas were clonal in origin (Figure
genetically matched, wild-type controls. Seventeen percent of 7C). Analysis of DNA isolated from representative B cell lympho-
inbred 129 Wnt5a heterozygous mice and twenty-five percent
mas revealed loss or reduction of the Wnt5a wild-type allele,
of C57Bl/6X129 (mixed background) Wnt5a heterozygous mice
indicating loss of heterozygousity (LOH) for Wnt5a in the tumordeveloped spontaneous B cell lymphoma or chronic myeloid
tissue (Figure 7D). To confirm loss of Wnt5a function in theleukemia by 24 months of age (Figure 7A). In contrast, age-
tumors, select tumors were isolated from representative miceand strain-matched wild-type control mice did not present with
and analyzed for the presence of Wnt5a protein by Westerntumors during this timeframe. Affected Wnt5a heterozygous
blot. Wnt5a was found to be absent in four of four tumor samplesmice presented with spleenomegaly and enlarged liver and
(Figure 7E). We also observed increased cyclin D1 levels inlymph glands. Moribund mice were sacrificed and analysis of
these tumor samples (Figure 7E). The loss of functional Wnt5athe tumor tissues was performed using physical staining and
in the tumors characterizes Wnt5a as a tumor suppressor in Bby antibody staining to confirm the tumor types (Figure 7B).
Thirty-eight percent of the observed tumors were B cell lympho- cell lymphoma and myeloid leukemia.
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Figure 6. Wnt5a suppresses cyclin D1 expression
A: Real-time PCR on total RNA extracted from E19 wild-type or Wnt5a null FL. The threshold cycle number (CT) for each sample was calculated with a
fluorescence threshold (Rn) of 0.03. Dashed line indicates the fluorescence threshold (Rn). Control real-time PCR using cyclin D1 cDNA as a standard is
also shown.
B: Transduction of Wnt5a into 7C6 or 1–8 mouse B cell lines activates the Wnt/Ca pathway and suppresses cyclin D1 levels.
C: Cell cycle analysis of asynchronously dividing B cells transduced with Wnt5a or empty vector. Transduction of Wnt5a into the transformed, Wnt5a null
B cell lines inhibits cell proliferation as determined by BrdU uptake (percentage of cells in S phase given).
Loss of WNT5A expression in primary human tissues. Eight AML samples and eight B cell ALL samples were
analyzed further for presence of the WNT5A gene. Southernleukemia tissue
To examine whether WNT5A might also function as a tumor analysis of genomic DNA purified from the tumor tissues was
performed using a probe against WNT5A exon 5 coding se-suppressor in human malignancies, primary tumor tissues from
ten human acute lymphoblastic leukemias (ALL, CD19, or quences. Several of the AML samples and half of the B cell ALL
samples displayed either loss or a large reduction in Wnt5aCD4) and ten acute myeloid leukemias (AML, CD13/CD33)
were examined for WNT5A expression by RT-PCR and Southern gene dosage (Figure 8B). Examination of cyclin D1 expression
levels in the eight primary ALL samples lacking WNT5A expres-analysis. WNT5A expression has been reported previously in
human B cell lines and myeloid cell lines and was readily de- sion and in the primary AML samples using real-time PCR re-
vealed a 4.7-fold increase (on average) in cyclin D1 expressiontected in normal human peripheral white blood cells as well as in
normal human CD34 bone marrow cells (Figure 8A). However, relative to normal control samples (Table 1).
eight ALL samples (pre-B cell ALL, CD19) lacked WNT5A tran-
scripts, whereas two ALL samples (one T cell ALL, CD4 and Discussion
CD19 and one mixed preB/myeloid cell ALL, CD19/CD33)
retained WNT5A expression. All of the myeloid leukemia sam- Previous studies have reported that Wnt5a induces cell prolifer-
ation, and Wnt5a is upregulated in a variety of human cancersples displayed either greatly reduced levels or complete ab-
sence of WNT5A transcripts. Therefore, loss of WNT5A expres- (Austin et al., 1997; Iozzo et al., 1995; Lejeune et al., 1995;
Saitoh and Katoh, 2001; Van Den Berg et al., 1998). In addition,sion correlates with tumorigenesis in human hematopoietic
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Figure 7. Wnt5a deficiency induces mouse tumor formation
A: Tumorigenesis in Wnt5a heterozygous mice. Wild-type 129 and 129xC57Bl/6 strain mice (circle) displayed no tumor formation during the time course of
the assay. Wnt5a heterozygous mice on a pure 129 strain background (triangle) or on a mixed 129xC57Bl/6 background (rectangle) presented with
spontaneous tumor formation. n  number of mice tested.
B: Wnt5a/ mice develop B cell lymphoma or chronic myeloid leukemia. Representative tumor sections harvested from Wnt5a/ mice. Serial sections
were stained with H&E or with B220 antibody. CML samples were confirmed by chloroacetate staining.
C: Ethidium bromide stained agarose gel of PCR results using five representative B cell mouse tumors with wild-type spleen as control.
D: Southern analysis of genomic DNA isolated from representative mouse B cell lymphoma demonstrating LOH for the wild-type Wnt5a allele.
E: Loss of Wnt5a correlates with tumor formation and increased cyclin D1. Representative tumor samples isolated from liver (W1122, W1126, W1483) or
spleen (W1083) and control tissue (Wnt5a/ non-tumor liver and spleen) were immunoblotted with anti-Wnt5a or cyclin D1 antibodies or anti--tubulin as
loading control.
exogenous expression of human Wnt5a has been recently found null mice proliferate more slowly than those derived from wild-
type littermates (data not shown).to induce melanoma progression and metastasis (Weeraratna
et al., 2002), further underscoring the oncogenic potential of Loss of Wnt5a leads to B cell lymphomas and myeloid leuke-
mias in Wnt5a heterozygous mice. Although onset of tumorigen-Wnt5a. Using genetically defined cells and mice, we now dem-
onstrate that Wnt5a negatively regulates progenitor B cell prolif- esis is quite rapid in some mice, the incomplete penetrance of
the tumor phenotype suggests that multiple molecular alter-eration and responsiveness to IL-7. The more rapid proliferation
of Wnt5a null cells in methylcellulose cultures, the increased ations are likely needed in the Wnt5a null cells in order for
tumorigenesis to occur. The reduction or absence of humanthymidine uptake exhibited by Wnt5a null cells in liquid culture,
and the increased numbers of B cells in the Rag1/ mice trans- Wnt5a expression in human primary tumor samples suggests
that loss of Wnt5a is a frequent event in these hematopoieticplanted with Wnt5a null FL indicate that Wnt5a-mediated regula-
tion of B cell proliferation is cell intrinsic. In addition, Wnt5a null tumors. Loss of Wnt5a gene dosage observed in several of the
primary tumors is also compelling, as presumably the cells werefetal liver cells respond similarly to IL-7 when grown on stromal
cells derived from Wnt5a null or wild-type mice, further confirm- not heterozygous prior to the onset of the disease. Thus, ab-
sence of WNT5A in these tumor tissues required the deletioning that Wnt5a functions in a cell-autonomous manner to regu-
late B cell proliferation. Lastly, reintroduction of Wnt5a into of both alleles. Absence of WNT5A expression was also ob-
served in four B cell ALL samples that retained WNT5A codingWnt5a-deficient B cell lines downregulated proliferation of the
transduced cells. The ability of Wnt5a to regulate cell growth sequences, suggesting that loss of WNT5A in these tumors
might be due to other mutations that either destabilize the RNAclearly is cell context dependent, as other tissues in the Wnt5a
null mice show reduced cell proliferation (Yamaguchi et al., or silence the WNT5A promoter. WNT5A expression was com-
pletely undetectable in eight acute B cell leukemias but was1999), and mouse embryonic fibroblasts derived from Wnt5a
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Figure 8. Loss of WNT5A and increased cyclin D1 in human cancer tissues
A: RNA samples extracted from patients and from healthy individuals were examined for WNT5A expression by RT-PCR and Southern blot hybridization.
Arrows indicate T cell or mixed myeloid/B cell lymphocytic leukemia sample.
B: Southern analysis of genomic DNA isolated from the patient primary tumors using WNT5A or human histone H4 cDNA as probes. Loss of WNT5A is observed
in tumor samples 1, 8, 12, 14, 17, and 19.
observed in one acute T cell leukemia and one mixed preB/ of Wnt5a in regulating B cell and T cell growth. The increase in
myeloid cell leukemia. Although Wnt5a is widely expressed in cyclin D1 expression in both mouse and human tumors lacking
hematopoietic development, the absence of T cell leukemia in Wnt5a corroborates the results of the fetal liver experiments
the Wnt5a het mice may therefore reflect differences in the role and transduction data, indicating that Wnt5a negatively regu-
lates cell proliferation and tumorigenesis by inhibiting cyclin D1
expression in hematopoietic tissues.
Development studies and cell differentiation studies using
Table 1. Cyclin D1 expression levels of human cancer samples various model systems have revealed that Wnt5a can signal
Normalized through both Wnt/-catenin pathway and Wnt/Ca pathway to
Leukemia Cyclin D1 GAPDH cyclin D1 Fold increase in cyclin regulate cell adhesion, mobility, proliferation, and differentiation
Patients type cyclesa cyclesa cyclesb D1 expressionc (He et al., 1997; Kuhl et al., 2000, 2001; Sheldahl et al., 1999;
Control Normal 23.05 17.06 23.05 — Toyofuku et al., 2000), and it has been proposed that the signal-
P1 AML 23.47 17.13 23.37 0.6 ing pathway induced by Wnt5a may depend upon the Frz recep-
P2 AML 22.41 16.78 22.78 0.5
tor type that binds Wnt5a (Holmen et al., 2002). Signaling byP3 AML 19.83 17.45 19.38 7.3
Wnt5a via the Wnt/Capathway results in the activation of PKCP4 AML 19.37 16.61 19.89 6.3
P5 AML 19.38 16.80 19.67 6.7 and CamKII and downregulation of Wnt/-catenin-responsive
P6 AML 20.46 17.22 20.26 5.5 gene transcription (Kuhl et al., 2001). To determine which path-
P7 AML 19.14 17.08 19.11 7.8 way mediates Wnt5a signaling in B cell development, we ana-P8 AML 20.21 17.17 20.08 5.9
lyzed activation of these pathways in Wnt5a null and wild-typeP9 AML 20.01 17.03 20.04 6.0
P10 AML 21.25 17.18 21.10 3.8 fetal liver tissue. Whole-cell and nuclear -catenin level re-
P12 PreB-ALL 21.07 16.75 21.45 3.1 mained unchanged in the presence or absence of Wnt5a, while
P14 PreB-ALL 20.41 17.17 20.27 5.5 activity of CamKII and PKC was decreased in Wnt5a null cells.
P15 PreB-ALL 21.14 17.27 20.88 4.3
Although expression of c-myc was unchanged in the absenceP16 PreB-ALL 19.82 17.2 19.65 6.7
of Wnt5a, expression of cyclin D1 was increased in Wnt5aP17 PreB-ALL 21.25 16.95 21.38 3.3
P18 preB-ALL 21.05 16.91 21.23 3.6 null cells. These results indicate that Wnt5a signals via the
P19 PreB-ALL 19.71 16.64 20.20 5.6 Wnt/Ca pathway to inhibit cyclin D1 expression. Because
P20 PreB-ALL 22.07 17.46 21.56 2.9
-catenin levels and c-myc expression levels were unchanged
a The threshold cycle number for each sample was calculated using the in the presence or absence of Wnt5a, it is unlikely that Wnt5a
Applied Biosystems ABI prism 7700 sequence detection system software at inhibits the Wnt/-catenin signaling cascade in these cells.a fluorescence threshold (Rn) of 0.011.
It is unclear at present how Wnt5a signaling via the Cab Threshold cycle numbers of the tumor samples were normalized for GAPDH.
c The increase in cyclin D1 expression was calculated by multiplying by two pathway inhibits cyclin D1 expression and B cell proliferation.
the difference between the normalized threshold cycle numbers of the A recent study in PKC knockout mice found that deletion of
tumor sample and of control. PKC led to increased B cell proliferation and autoimmunity
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Flow cytometry(Miyamoto et al., 2002). Since total phosphorylated PKC was
Single-cell suspensions were prepared from E19 FL and stained with anti-found to be lower in the Wnt5a null cells in our study, this
B220-APC (Caltag Laboratory), -CD43-PE (PharMingen), IgM-FITC (Phar-PKC isoform is also likely to be downregulated in these cells.
Mingen). The analysis was performed with FACSCalibur flow cytometer (Bec-
Furthermore, several lines of evidences indicate that CamKII ton Dickinson) and FlowJo software (Tree Star, Inc.).
activation exerts a dominant inhibitory effect on gene transcrip-
Fluorescence-activated cell sorting (FACS)tion by phosphorylating CREB, the cAMP response element
Single-cell suspensions were prepared from FL, bone marrow, and spleenbinding protein (Sun et al., 1994; Wu and McMurray, 2001).
of 6- to 8-week-old mice and were antibody stained and sorted using FACS-Cyclin D1, unlike c-Myc, contains a cAMP-responsive element
Vantage (Becton Dickinson).in its promoter region, and it is possible that the increased
cyclin D1 mRNA levels seen in Wnt5a null cells are results from Colony forming assays
attenuation of CamKII activity. Thus, Wnt5a-mediated activation Cells were prepared from E19.5 Wnt5a/ and / FL, and 9 104 cells were
plated in methylcellulose media M3630 supplemented with IL-7, accordingof both CamKII and PKC may function to inhibit B cell prolifera-
to the manufacturer’s instructions (StemCell Technologies). Colonies (50tion.
cells) were counted 7 days later using an inverted microscope at 40magni-In summary, our studies reveal that Wnt5a negatively regu-
fication.
lated B cell proliferation and response to IL-7 through the Wnt/
Ca signaling pathway. Loss of Wnt5a expression in both mice BrdU analysis
and human tumors indicates that Wnt5a suppresses tumorigen- Mice were injected intraperitoneally with 50 g BrdU/gram body weight on
the 18th day of pregnancy. Embryos were harvested 1 hr after injection, andesis in these hematopoietic tissues. To our knowledge, this is
the fetal liver removed and stained with anti-B220-APC and sorted. Cellsthe first demonstration that any member of the Wnt family of
were subsequently stained with anti-Brdu-FITC (Becton Dickinson) ac-protooncogenes can function as a tumor suppressor. Our con-
cording to supplier’s instruction and analyzed by flow cytometry as above.
clusion is supported in part by previous experiments in which
ectopic expression of WNT5A in a transformed uroepithelial cell B cell proliferation assays
line showed inhibition of cell growth (Olson et al., 1997) and Sorted 2  105 B220-positive cells were plated into wells of 96-well plates
with 200 l of RPMI supplemented with 10% FCS, 2 mM L-glutanine, 100transfection of antisense WNT5A into C57MG mammary epithe-
g/ml streptomycin, 100 U/ml penicillin, and 50 M 2-mercaptoethanollial cells induced a transformed cell morphology (Olson and Gibo,
(GIBCO-BRL) in the presence or absence of IL-7 (0.5 ng/ml, StemCell Tech-1998). Wnt5a signaling could be a potential therapeutic target
nologies). Following 48 hr of culture at 37	C and 10% CO2, cells were pulsed
for the treatment of acute lymphocytic leukemia and myeloid with [3H] thymidine (1 Ci per well) for 16 hr prior to harvest. Incorporated
leukemia. Further studies on the role of Wnt5a in myeloid cell radioactivity was quantified with a Liquid Scintillation and Luminescence
Counter (Perkin Elmer Wallac Inc.).proliferation and differentiation, as well as characterization of
additional functional roles for Wnt5a in hematopoietic develop-
Transduction of B cellsment, are presently ongoing.
Mouse Wnt5a cDNA (Upstate Biotechnologies) was inserted into the
pMSCV2.2 IRES-GFP vector. The 7C6 and 1–8 mouse B cell lines were
Experimental procedures
cultured in RPMI supplemented with 10% FCS, 2 mM L-glutanine, 100 g/
ml streptomycin, 100 U/ml penicillin, and 50 M 2-mercaptoethanol (GIBCO-
Generation of Wnt5a null embryos
BRL). Control vector or Wnt5a expression vector was transduced into cells
Mice bearing a functionally inactivated allele of Wnt5a were generated pre-
using a Gene Pulser II (BioRad) electroporator at 275 V, 950 F, and GFP-
viously (Yamaguchi et al., 1999). In order to maintain an inbred genetic
positive cells were sorted by FACS. Transduced cells were harvested for
background in these studies, germline-transmitting Wnt5a chimeric mice
Western blot analysis as well as propidium iodide and BrdU staining at 48
were bred with 129SvBrd mice to establish 129-strain mice bearing the Wnt5a to 72 hr post-electroporation.
null allele. Embryos were harvested from intercrosses of these Wnt5a hetero-
zygous mice, and Wnt5a null mice were initially identified by morphology. Adoptive transplantation of fetal livers
The genotypes of all samples were subsequently confirmed by PCR. Rag1/ mice (C57BL/6 strain, from Jackson Laboratory) were used as
recipients and received 900 cGy 
-irradiation (137Cs source, dose rate 81
Analysis of RNA by RT-PCR and Southern blots cGy/min) 4 hr before cell transfer. 5  106 cells prepared from E16 FL were
Total RNA was prepared using TRIzol (Invitrogen). Reverse transcription with injected intravenously into the recipient mice. Bone marrow, spleen, and
polymerase chain reaction (RT-PCR) assay was carried out using Super- peripheral blood cells were harvested for flow cytometry analysis at 6 weeks
Script One-Step RT-PCR with Platinum Taq kit (Invitrogen). Primer se- post-transplantation.
quences (from 5 to 3) are human WNT5A, forward: ctacgagagtgctcgcatcct
catg, reverse: cattgcgcacgcagtagtcag; mouse Wnt5a, forward: tcgggactgg Kinase activity assays
ttgtgggg, reverse: agctcgcagccgtccatc; human GAPDH, forward: cagcct Fetal liver was lysed by sonication in 50 mM Hepes, 270 mM KCl, 0.1 mM.
caagatcatcagca, reverse: tgagcttgacaaagtggtcg; mouse Gapdh, forward: EDTA, 0.1 mM EGTA, 10% glycerol, and 1% NP40. Protein was recovered
caccatggagaaggccgggg; reverse: gacggacacattgggggtag. The RT-PCR cy- by centrifugation and concentrations were determined using BCA Protein
cling parameters are 48	C for 30 s; 94	C for 2 min; then followed by 26 Assays (Pierce). CamKII activity was measured by using a CaM Kinase II
cycles (for GAPDH) or 42 cycles (for human and mouse Wnt5a) at 94	C for Assay Kit (Upstate) and 100 g protein extract according to supplier’s in-
30 s, 55	C (for human WNT5A), or 60	C (for mouse Wnt5a and GAPDH of struction. Incorporated radioactivity was monitored with Multi-Purpose Scin-
both mouse and human) for 30 s and 72	C for 1 min with a final extension tillation Counter (Beckman Instruments, Inc.). JNK kinase assays were per-
of 72	C for 10 min after the last cycle. Following RT-PCR and gel electropho- formed using immunoprecipitates of JNK as previously described
resis, Southern analysis was performed to confirm the identity of the Wnt5a (Raingeaud et al., 1995), with phosphorylation of c-Jun detected using phos-
PCR fragments. pho-c-Jun antibody (Ser63) (Cell Signaling Technology).
Stromal cell primary culture Western blotting
Cells prepared from E17 FL of wild-type and Wnt5a null mice and from Cells or tissues were lysed with 1% NP40, 0.5% sodium deoxylate, 0.1%
6-week-old wild-type mouse bone marrow were cultured as described pre- SDS, and protease inhibitor cocktail tables (Complete) in PBS. Proteins were
separated by 10% SDS-polyacrylamide gel electrophoresis and transferredviously (Whitlock et al., 1984).
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to nitrocellulose membrane (BIO-RAD). Immunoblots were probed with pri- comments on this manuscript. Core facilities used to perform some of these
experiments were supported by Program Project Grant 5P30DK32520 frommary antibodies against Wnt5a (R&D System), CamKII, cyclin D1 (Santa
Cruz Biotechnology, Inc.), JNK (Cell signaling), phosphorylated-PKC-pan the National Institute of Diabetes and Digestive and Kidney Diseases. This
research was supported by NIH grant CA77735 to S.N.J.(Cell Signaling), or -catenin-Exon 3 (Calbiochem), then with anti-IgG-HRP
antibodies, and visualized using ECL (Amersham Pharmacia Biotech) ac-
cording to the supplier’s instructions.
Quantitative real-time PCR (QRT-PCR) Received: March 19, 2003
Relative quantities of mRNA expression were analyzed using QRT-PCR Revised: July 30, 2003
(Applied Biosystems ABI Prism 7700 Sequence Detection System, Applied Published: November 24, 2003
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